Search Results - "Rubio, Eduardo Díaz"

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study by SALTZ, Leonard B, CLARKE, Stephen, COUTURE, Felix, SIRZEN, Florin, CASSIDY, Jim, DIAZ-RUBIO, Eduardo, SCHEITHAUER, Werner, FIGER, Arie, WONG, Ralph, KOSKI, Sheryl, LICHINITSER, Mikhail, YANG, Tsai-Shen, RIVERA, Fernando

“…To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or…”
Get full text

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer by CASSIDY, Jim, CLARKE, Stephen, COUTURE, Felix, SIRZEN, Florin, SALTZ, Leonard, DIAZ-RUBIO, Eduardo, SCHEITHAUER, Werner, FIGER, Arie, WONG, Ralph, KOSKI, Sheryl, LICHINITSER, Mikhail, YANG, Tsai-Shen, RIVERA, Fernando

“…To evaluate whether capecitabine plus oxaliplatin (XELOX) is noninferior to fluorouracil. folinic acid, and oxaliplatin (FOLFOX-4) as first-line therapy in…”
Get full text

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer by García-Foncillas, Jesús, Tabernero, Josep, Élez, Elena, Aranda, Enrique, Benavides, Manuel, Camps, Carlos, Jantus-Lewintre, Eloisa, López, Rafael, Muinelo-Romay, Laura, Montagut, Clara, Antón, Antonio, López, Guillermo, Díaz-Rubio, Eduardo, Rojo, Federico, Vivancos, Ana

“…Background Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was…”
Get full text

First‐Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single‐Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study by Díaz‐Rubio, Eduardo, Gómez‐España, Auxiliadora, Massutí, Bartomeu, Sastre, Javier, Abad, Albert, Valladares, Manuel, Rivera, Fernando, Safont, Maria J., Martínez de Prado, Purificación, Gallén, Manuel, González, Encarnación, Marcuello, Eugenio, Benavides, Manuel, Fernández‐Martos, Carlos, Losa, Ferrán, Escudero, Pilar, Arrivi, Antonio, Cervantes, Andrés, Dueñas, Rosario, López‐Ladrón, Amelia, Lacasta, Adelaida, Llanos, Marta, Tabernero, Jose M., Antón, Antonio, Aranda, Enrique

“…Purpose. The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus…”
Get full text

SOD3 improves the tumor response to chemotherapy by stabilizing endothelial HIF-2α by Mira, Emilia, Carmona-Rodríguez, Lorena, Pérez-Villamil, Beatriz, Casas, Josefina, Fernández-Aceñero, María Jesús, Martínez-Rey, Diego, Martín-González, Paula, Heras-Murillo, Ignacio, Paz-Cabezas, Mateo, Tardáguila, Manuel, Oury, Tim D., Martín-Puig, Silvia, Lacalle, Rosa Ana, Fabriás, Gemma, Díaz-Rubio, Eduardo, Mañes, Santos

“…One drawback of chemotherapy is poor drug delivery to tumor cells, due in part to hyperpermeability of the tumor vasculature. Extracellular superoxide…”
Get full text

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database by Shi, Qian, de Gramont, Aimery, Grothey, Axel, Zalcberg, John, Chibaudel, Benoist, Schmoll, Hans-Joachim, Seymour, Matthew T, Adams, Richard, Saltz, Leonard, Goldberg, Richard M, Punt, Cornelis J A, Douillard, Jean-Yves, Hoff, Paulo M, Hecht, Joel Randolph, Hurwitz, Herbert, Díaz-Rubio, Eduardo, Porschen, Rainer, Tebbutt, Niall C, Fuchs, Charles, Souglakos, John, Falcone, Alfredo, Tournigand, Christophe, Kabbinavar, Fairooz F, Heinemann, Volker, Van Cutsem, Eric, Bokemeyer, Carsten, Buyse, Marc, Sargent, Daniel J

“…Progression-free survival (PFS) has previously been established as a surrogate for overall survival (OS) for first-line metastatic colorectal cancer (mCRC)…”
Get full text

Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer by Tabernero, Josep, Van Cutsem, Eric, Díaz-Rubio, Eduardo, Cervantes, Andrés, Humblet, Yves, André, Thierry, Van Laethem, Jean-Luc, Soulié, Patrick, Casado, Esther, Verslype, Chris, Valera, Javier Sastre, Tortora, Giampaolo, Ciardiello, Fortunato, Kisker, Oliver, de Gramont, Aimery

“…This phase II study investigated the efficacy and safety of cetuximab combined with standard oxaliplatin-based chemotherapy (infusional fluorouracil,…”
Get full text

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial by DIAZ-RUBIO, Eduardo, TABERNERO, Jose, MAUREL, Joan, GONZALEZ-FLORES, Encarnacion, APARICIO, Jorge, RIVERA, Fernando, LOSA, Ferran, ARANDA, Enrique, GOMEZ-ESPANA, Auxiliadora, MASSUTI, Bartomeu, SASTRE, Javier, CHAVES, Manuel, ABAD, Alberto, CARRATO, Alfredo, QUERALT, Bernardo, REINA, Juan José

“…The aim of this phase III trial was to compare the efficacy and safety of capecitabine plus oxaliplatin (XELOX) versus Spanish-based continuous-infusion…”
Get full text

Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First‐Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study by Sastre, Javier, Maestro, M. Luisa, Gómez‐España, Auxiliadora, Rivera, Fernando, Valladares, Manuel, Massuti, Bartomeu, Benavides, Manuel, Gallén, Manuel, Marcuello, Eugenio, Abad, Albert, Arrivi, Antonio, Fernández‐Martos, Carlos, González, Encarnación, Tabernero, Josep M., Vidaurreta, Marta, Aranda, Enrique, Díaz‐Rubio, Eduardo

“…Background. The Maintenance in Colorectal Cancer trial was a phase III study to assess maintenance therapy with single‐agent bevacizumab versus bevacizumab…”
Get full text

First‐Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study by Sastre, Javier, Grávalos, Cristina, Rivera, Fernando, Massuti, Bartomeu, Valladares‐Ayerbes, Manuel, Marcuello, Eugenio, Manzano, José L., Benavides, Manuel, Hidalgo, Manuel, Díaz‐Rubio, Eduardo, Aranda, Enrique

“…Single‐agent cetuximab is safe and active in elderly patients with advanced colorectal cancer (CRC). A cetuximab–capecitabine combination has not previously…”
Get full text

XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer by CASSIDY, Jim, TABERNERO, Josep, SCHÖFFSKI, Patrick, SOBRERO, Alberto, VAN CUTSEM, Eric, DIAZ-RUBIO, Eduardo, TWELVES, Chris, BRUNET, René, BUTTS, Charles, CONROY, Thierry, DEBRAUD, Filippo, FIGER, Arie, GROSSMANN, Johannes, SAWADA, Noriaki

“…Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC). Oxaliplatin shows synergy with fluorouracil (FU),…”
Get full text

Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? by Aguado, Carlos, García-Paredes, Beatriz, Sotelo, Miguel Jhonatan, Sastre, Javier, Díaz-Rubio, Eduardo

“…Fluoropyrimidines play a central role in the first-line treatment of metastatic colorectal cancer.Our aim was to review whether capecitabine was a…”
Get full text

Nasoethmoidal Intestinal‐Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti‐Epidermal Growth Factor Receptor Therapy by Cabezas‐Camarero, Santiago, de la Orden García, Virginia, García‐Barberán, Vanesa, Mediero‐Valeros, Beatriz, Subhi‐Issa, Ahmad Issa, Llovet García, Patricia, Bando‐Polaino, Inmaculada, Merino Menéndez, Salomé, Pérez‐Segura, Pedro, Díaz‐Rubio, Eduardo

“…Sinonasal intestinal‐type adenocarcinomas (SNS‐ITAC) are very rare tumors that resemble colorectal cancer in many of their pathological and molecular…”
Get full text

Role of cetuximab in first-line treatment of metastatic colorectal cancer by Sotelo, Miguel Jhonatan

“…The treatment of metastatic colorectal cancer(mCRC)has evolved considerably in the last decade,currently allowing most mCRC patients to live more than two…”
Get full text

SOD3 induces a HIF-2α-dependent program in endothelial cells that provides a selective signal for tumor infiltration by T cells by Carmona-Rodríguez, Lorena, Martínez-Rey, Diego, Fernández-Aceñero, Maria Jesús, González-Martín, Alicia, Paz-Cabezas, Mateo, Rodríguez-Rodríguez, Noe, Pérez-Villamil, Beatriz, Sáez, Maria Eugenia, Díaz-Rubio, Eduardo, Mira, Emilia, Mañes, Santos

“…BackgroundTumor-infiltrating lymphocytes (TILs), mainly CD8+ cytotoxic T lymphocytes (CTL), are linked to immune-mediated control of human cancers and response…”
Get full text

Continuing Single‐Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First‐Line Treatment of Metastatic Colorectal Cancer by Díaz‐Rubio, Eduardo, Pietrantonio, Filippo, Braud, Filippo

“…Section Editor's Note: Metastatic colorectal cancer is the second leading cause of cancer death in the United States. Since 1995, treatment regimens have…”
Get full text

Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome by Lorca, Víctor, Rueda, Daniel, Martín-Morales, Lorena, Poves, Carmen, Fernández-Aceñero, María Jesús, Ruiz-Ponte, Clara, Llovet, Patricia, Marrupe, David, García-Barberán, Vanesa, García-Paredes, Beatriz, Pérez-Segura, Pedro, de la Hoya, Miguel, Díaz-Rubio, Eduardo, Caldés, Trinidad, Garre, Pilar

“…The involvement of GALNT12 in colorectal carcinogenesis has been demonstrated but it is not clear to what extent it is implicated in familial CRC…”
Get full text

Chemotherapy for gastric cancer by Javier Sastre Jose Angel García-Saenz Eduardo Díaz-Rubio

“…Metastatic gastric cancer remains a non-curative disease. Palliative chemotherapy has been demonstrated to prolong survival without quality of life compromise…”
Get full text

About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants by Gutiérrez‐Enríquez, Sara, Bonache, Sandra, Ruíz de Garibay, Gorka, Osorio, Ana, Santamariña, Marta, Ramón y Cajal, Teresa, Esteban‐Cardeñosa, Eva, Tenés, Anna, Yanowsky, Kira, Barroso, Alicia, Montalban, Gemma, Blanco, Ana, Cornet, Mònica, Gadea, Neus, Infante, Mar, Caldés, Trinidad, Díaz‐Rubio, Eduardo, Balmaña, Judith, Lasa, Adriana, Vega, Ana, Benítez, Javier, la Hoya, Miguel, Diez, Orland

“…RAD51D mutations have been recently identified in breast (BC) and ovarian cancer (OC) families. Although an etiological role in OC appears to be present, the…”
Get full text

Capillary Electrophoresis Analysis of Conventional Splicing Assays: IARC Analytical and Clinical Classification of 31 BRCA2 Genetic Variants by de Garibay, Gorka Ruiz, Acedo, Alberto, García-Casado, Zaida, Gutiérrez-Enríquez, Sara, Tosar, Alicia, Romero, Atocha, Garre, Pilar, Llort, Gemma, Thomassen, Mads, Díez, Orland, Pérez-Segura, Pedro, Díaz-Rubio, Eduardo, Velasco, Eladio A., Caldés, Trinidad, de la Hoya, Miguel

“…ABSTRACT Rare sequence variants in “high‐risk” disease genes, often referred as unclassified variants (UVs), pose a serious challenge to genetic testing…”
Get full text